DOI: https://doi.org/10.22141/2663-3272.2.2.2019.176028

Glutathione system — a promising target for increasing sensitivity to chemotherapeutic drugs (literature review)

A.V. Postupalenko, Yu.I. Zaivelieva, O.S. Zotov

Abstract


The review considers the role of the glutathione system in the context of the treatment for malignant neoplasms that has been actively studied for several decades. Its functioning is vital for maintaining the redox homeostasis of normal cells of the human body; at the same time, numerous correlations of this system with the development and progression of malignant neoplasms are established. Given the important role of glutathione in cell death and development of resistance to chemotherapeutic compounds, a further search for levers of influence on glutathione-mediated mechanisms is promising.

Keywords


redox potential; glutathione; malignant neoplasms; antitumor therapy; overview

References


Lu S.C. Glutathione synthesis. Biochim Biophys Acta. 2013. 1830. 3143-3153.

Balendiran G.K., Dabur R., Fraser D. The role of glutathione in cancer. Cell Biochem Funct. 2004. 22. 343-352.

Estrela J.M., Ortega A., Obrador E. Glutathione in cancer biology and therapy. Crit. Rev. Clin. Lab. Sci. 2006. 43. 143-181.

Hussain S.P., Hofseth L.J., Harris C.C. Radical causes of cancer. Nat. Rev. Cancer. 2003. 3. 276-285.

Tafani M., Sansone L., Limana F., Arcangeli T., De Santis E., Polese M., Fini M., Russo M.A. The interplay of reactive oxygen species, hypoxia, inflammation, and sirtuins in cancer initiation and progression. Oxid Med. Cell Longev. 2016. 3907147. 2016.

Hatem E., El Banna N., Huang M.E. Multifaceted Roles of Glutathione and Glutathione-Based Systems in Carcinogenesis and Anticancer Drug Resistance. Antioxid Redox Signal. 2017 Nov 20. 27(15). 1217-1234.

Di Pietro G., Magno L.A., Rios-Santos F. Glutathione S-transferases: an overview in cancer research. Expert Opin. Drug Metab. Toxicol. 2010. 6. 153-170.

Hayes J.D., Flanagan J.U., Jowsey I.R. Glutathione transferases. Ann. Rev. Pharmacol. Toxicol. 2005. 45. 51-88.

Bartoli G.M., Sies H. Reduced and oxidized glutathione efflux from liver. FEBS Lett. 1978. 86(1). 89-91.

Traverso N., Ricciarelli R., Nitti M., Marengo B., Furfaro A.L., Pronzato M.A., Marinari U.M., Domenicotti C. Role of glutathione in cancer progression and chemoresistance. Oxid Med. Cell Longev. 2013. 2013. 972913.

Shibata S., Tominaga K., Watanabe S. Glutathione protects against hypoxic/hypoglycemic decreases in 2-deoxyglucose uptake and presynaptic spikes in hippocampal slices. Eur. J. Pharmacol. 1995 Jan 24. 273(1-2). 191-5.

Chakrapani H., Kalathur R.C., Maciag A.E., Citro M.L., Ji X., Keefer L.K., Saavedra J.E. Synthesis, mechanistic studies, and anti-proliferative activity of glutathione/glutathione S-transferase-activated nitric oxide prodrugs. Bioorg Med. Chem. 2008 Nov 15. 16(22). 9764-71.

Wu J.H., Miao W., Hu L.G., Batist G. Identification and characterization of novel Nrf2 inducers designed to target the intervening region of Keap1. Chem. Biol. Drug Des. 2010 May. 75(5). 475-80.

Hamilton D., Batist G. TLK-199 Telik. IDrugs. 2005 Aug. 8(8). 662-9.

Fidias P., Novello S. Strategies for prolonged therapy in patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 2010 Dec 1. 28(34). 5116-23.

Matulonis U.A., Horowitz N.S., Campos S.M., Lee H., Lee J, Krasner C.N., Berlin S., Roche M.R., Duska L.R., Pereira L., Ken­dall D., Penson R.T. Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer. J. Clin. Oncol. 2008 Dec 10. 26(35). 5761-6.

Fruehauf J.P., Meyskens F.L. Jr. Reactive oxygen species: a breath of life or death? Clin. Cancer Res. 2007 Feb 1. 13(3). 789-94.

Pljesa-Ercegovac M., Savic-Radojevic, Matic M., Coric V., Djukic T., Radic T., Simic T. Glutathione Transferases: Potential Targets to Overcome Chemoresistance in Solid Tumors. Int. J. Mol. Sci. 2018 Nov 28. 19(12). pii: E3785.

Singh S. Cytoprotective and regulatory functions of glutathione S-transferases in cancer cell proliferation and cell death. Cancer Chemother. Pharmacol. 2015. 75. 1-15.

Corso C.R., Acco A. Glutathione system in animal model of solid tumors: From regulation to therapeutic target. Crit. Rev. Oncol. Hematol. 2018 Aug. 128. 43-57.

Cohen S.J., Zalupski M.M., Conkling P., Nugent F., Ma W.W., Modiano M., Pascual R., Lee F.C., Wong L., Hersh E. A phase 2 randomized, double-blind, multicenter trial of imexon plus gemcitabine versus gemcitabine plus placebo in patients with metastatic chemotherapy-naïve pancreatic adenocarcinoma. Am. J. Clin. Oncol. 2018 Mar. 41(3). 230-235.

Raza A., Galili N., Smith S.E., Godwin J., Boccia R.V., Myint H., Mahadevan D., Mulford D., Rarick M., Brown G.L., Schaar D., Faderl S., Komrokji R.S., List A.F., Sekeres M. A phase 2 randomized multicenter study of 2 extended dosing schedules of oral ezatiostat in low to intermediate-1 risk myelodysplastic syndrome. Cancer. 2012 Apr 15. 118(8). 2138-47.

Nechushtan H., Hamamreh Y., Nidal S., Gotfried M., Ba­ron A., Shalev Y., Nisman B., Peretz T., Peylan-Ramu N. A phase IIb trial assessing the addition of disulfiram to chemotherapy for the treatment of metastatic non-small cell lung cancer. Oncologist. 2015 Apr. 20(4). 366-7.

Townsend D.M., He L., Hutchens S., Garrett T.E., Pazoles C.J., Tew K.D. NOV-002, a glutathione disulfide mimetic, as a modulator of cellular redox balance. Cancer research. 2008. 68(8). 2870-2877.

Townsend D.M., Pazoles C.J., Tew K.D. NOV-002, a mimetic of glutathione disulfide. Expert opinion on investigational drugs. 2008. 17(7). 1075-1083.

https://clinicaltrials.gov/ct2/show/results/NCT00347412? term=NOV-002&rank=3

Montero A.J., Diaz-Montero C.M., Deutsch Y.E. et al. Phase 2 study of neoadjuvant treatment with NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel in patients with HER-2 negative clinical stage II-IIIc breast cancer. Breast Cancer Res Treat. 2012 Feb. 132(1). 215-23. doi: 10.1007/s10549-011-1889-0. Epub 2011 Dec.

Манихас Г.М., Филатова Е.И., Антонов В.Г. Применение препарата глутоксима при сочетанной лучевой терапии местно-распространенного рака шейки матки. Российский онкологический журнал. 2008. 1. 23-28.

Манихас Г.М., Жукова Н.В. Качество жизни больных местнораспространенным оперированным раком желудка на этапах химиотерапевтического лечения. Вопросы онкологии. 2012. 5. 679-683.

Богуш Т.А., Дудко Е.А., Богуш Е.А., Кирсанов В.Ю., Антонов В.Г. Глутоксим как ингибитор фенотипа множественной лекарственной резистентности, ассоциированной с экспрессией Рgp. Антибиотики и химиотерапия. 2010. 55. 5-6.

Kozhemyakin L., Ketlinskaya O., Romanova S. et al. New Generation Drugs at Treatment of Viral Hepatitis: Differentiated Effect on Normal and Virus-Infected Cells. ExConsilio. 1999. 1. 59-65.


Refbacks

  • There are currently no refbacks.


Copyright (c) 2019 Practical oncology

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2020

 

   Seo анализ сайта